HC Wainwright Cuts Neurogene (NASDAQ:NGNE) Price Target to $45.00

Neurogene (NASDAQ:NGNE) had its price objective lowered by HC Wainwright from $50.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Neurogene’s Q2 2025 earnings at ($1.06) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($4.30) EPS, Q1 2026 earnings at ($1.11) EPS, Q2 2026 earnings at ($1.12) EPS, Q3 2026 earnings at ($1.14) EPS, Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.52) EPS.

A number of other analysts have also recently commented on NGNE. BMO Capital Markets cut their price target on shares of Neurogene from $45.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. William Blair reiterated an “outperform” rating on shares of Neurogene in a research note on Tuesday, March 25th. Finally, Robert W. Baird set a $38.00 price target on shares of Neurogene in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Neurogene currently has an average rating of “Buy” and an average price target of $46.20.

Neurogene Trading Up 27.3%

Shares of NGNE opened at $19.37 on Tuesday. Neurogene has a 12 month low of $6.88 and a 12 month high of $74.49. The firm has a fifty day simple moving average of $13.48 and a 200 day simple moving average of $20.82. The stock has a market capitalization of $276.25 million, a price-to-earnings ratio of -4.45 and a beta of 1.56.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.03). As a group, research analysts predict that Neurogene will post -4.27 earnings per share for the current fiscal year.

Insider Transactions at Neurogene

In other news, insider Stuart Cobb sold 6,797 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.15, for a total transaction of $102,974.55. Following the completion of the sale, the insider now owns 20,794 shares in the company, valued at approximately $315,029.10. This trade represents a 24.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Christine Mikail Cvijic sold 4,501 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This represents a 5.86% decrease in their position. The disclosure for this sale can be found here. 11.64% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurogene

A number of hedge funds have recently modified their holdings of NGNE. GAMMA Investing LLC lifted its stake in shares of Neurogene by 2,985.1% during the 1st quarter. GAMMA Investing LLC now owns 4,134 shares of the company’s stock worth $48,000 after buying an additional 4,000 shares during the last quarter. Corebridge Financial Inc. increased its position in Neurogene by 13.8% during the first quarter. Corebridge Financial Inc. now owns 5,826 shares of the company’s stock worth $68,000 after acquiring an additional 705 shares during the period. PNC Financial Services Group Inc. bought a new position in Neurogene during the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. bought a new position in Neurogene during the fourth quarter worth about $72,000. Finally, Virtus ETF Advisers LLC increased its position in Neurogene by 45.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after acquiring an additional 989 shares during the period. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.